It's another week of debate over PBS deferrals. Unfortunately, there appears to be an effort to limit public discussion. Given the obvious risk to patients and the implications for the access agenda, which is flailing against the backdrop of deferrals, how does that make sense? It also stands in stark contrast to when cost recovery was introduced. …
Latest Video
New Stories
-
The 'Week in Review' Podcast - 1 November
November 1, 2024 - - Podcast -
Liz Selby goes from acting to permanent head of Sanofi's local pharmaceutical business
November 1, 2024 - - Latest News -
Arrotex partners with Juniper to deliver new rare blood cancer treatment
November 1, 2024 - - Latest News -
Pharmac proposes expanding access to Amgen's osteoporosis biologic
November 1, 2024 - - Latest News -
Rebates are by far the fastest growing component of PBS spend
October 31, 2024 - - Latest News -
This circular and semantic argument ends with one conclusion - a submission cap
October 31, 2024 - - Latest News -
This would be the most significant change in PBS decision-making in over 30 years
October 31, 2024 - - Latest News